The differential diagnosis includes infection was indistinguishable from *Moraxella osloensis*. Clinically, this patient’s results were negative. A RapID NH panel (Remel, Lenexa, KS, USA) was performed that identified the isolate as *M. osloensis* with a 99.7% probability. Ideally, the isolate would have undergone more comprehensive genotypic and phenotypic characterization. However, as a presumed *Neisseria* species, it was subjected to the usual testing protocol at the health department. Chlamydial culture was performed by using buffalo green monkey kidney cells (Viromed, Minnetonka, MN, USA) grown under standard conditions. No viral inclusions were seen, and the culture did not react with chlamydial antibodies (Trinity Biotech, Bray, Ireland). Because the child responded rapidly to antimicrobial drug treatment, no further workup of the bacterial isolate was considered. The child was healthy 3 days later and was discharged to his home with topical erythromycin and instructions to his parents to follow up with his primary care physician.

Neonatal ophthalmia is a potentially serious, sight-threatening infection that may be caused by sexually transmitted pathogens. Accordingly, this clinical presentation warrants prompt microbiologic diagnosis and appropriate therapy. At the same time, suspicion of a sexually transmitted disease causes immense social turmoil. Specific bacterial cultures are essential for precise microbiologic diagnosis and treatment.

Cultures of conjunctival specimens from our patient grew *Moraxella osloensis*. Clinically, this patient’s infection was indistinguishable from other causes of neonatal ophthalmia. The differential diagnosis includes other agents such as *N. gonorrhoeae*, *Chlamydia trachomatis*, *M. catarrhalis*, *Staphylococcus aureus*, *Haemophilus influenzae*, and *Streptococcus pneumoniae*. Rarely, gram-negative enteric organisms may be implicated (9). Viruses, such as adenovirus or herpesvirus, are also a potential cause but were unlikely in this case.

Finally, social issues must be considered. When an infant is seen with neonatal ophthalmia, a physician will often presume it to be gonococcal or chlamyial and assume the mother is positive for these infections. Recognizing that *Moraxella* species, including *M. osloensis*, may produce an identical clinical picture should limit presumptions regarding sexually transmitted diseases until a precise microbiologic diagnosis is made.

Andrew Walls* and Ellen Wald†
*University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA; and †University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

References


Address for correspondence: Andrew Walls, Department of Pathology, UPMC Presbyterian, C901, 200 Lothrop St, Pittsburgh, PA 15213, USA; fax: 412-624-0614; email: wallsal@upmc.edu

---

**African Tick-bite Fever in French Travelers**

**To the Editor:** African tick-bite fever (ATBF) is caused by *Rickettsia africanae* and remains the most common tick-borne rickettsiosis in sub-Saharan Africa (1,2). We describe an outbreak of ATBF in 10 of 34 French tourists on their return from South Africa in March 2005. Fever, skin rash, and multiple eschars on the legs developed in the index case-patient (patient 9, Table). After infected consent was obtained, the tourists completed a questionnaire for epidemiologic and clinical data. Acute- and convalescent-phase serum samples were collected when possible for serologic analysis performed at the Unité des Rickettsies. The samples were tested against a panel of antigens including *R. typhi*, *Francisella tularensis*, *Coxiella burnetii*, *Borrelia burgdorferi*, *Anaplasma phagocytophylum*, *R. felis*, *R. helvetica*, *R. conorii* subsp. *conorii* strain Malish, *R. africanae*, *R. sibirica mongolotimonae*, *R. massili- ae*, and *R. slovaca*, as previously described (3). A case of symptomatic confirmed ATBF was defined as clinical illness and positive serologic results against *R. africanae*, whereas a case of probable ATBF was defined as typical clinical symptoms without
definite serologic evidence of *R. africae* infection.

Of the 34 travelers, 30 completed the questionnaire and 20 consented to give at least 1 serum sample. After their return to France, symptoms compatible clinically with ATBF developed in 10 of the travelers (Table) and 9 had positive serologic results and/or a seroconversion for spotted fever group–rickettsia, including *R. africae* (Table). The median time from illness onset to serum testing was 19 days. Thus, 9 of the travelers had probable and 1 had possible (no serum was available) ATBF. Including both probable and possible cases, the illness rate for the whole group was 33.3% (10/30). None of the travelers reported a history of tick bite. The delay between probable exposure and onset of symptoms was 3–10 days (mean ± standard deviation 6.1 ± 1.9 days). Multiple eschars on the legs or arms were seen in 7 (70%) of 10 patients. Eight patients received doxycycline (200 mg per day) for a mean of 10.8 ± 5.9 days (range 5–20), 1 patient received pristinamycin for 8 days, and 1 patient received no treatment. All patients recovered fully without sequel; however, 6 patients reported convalescent-phase asthenia and 1 reported chronic insomnia, which had not occurred previously, for 2 months after the illness. Among the 10 remaining travelers, for whom a serum sample was available, with no clinical evidence of ATBF, 5 were positive for *R. africae* with only immunoglobulin M (IgM) at a titer of 1:32 in 4 cases and IgG at 1:128 with IgM at 1:32 in 1 case (an acute-phase serum from this patient showed IgG at 1:32 and IgM at 1:32). The 5 other travelers had negative serologic results. Results of serologic testing for other bacteria were negative for all travelers. Twenty-four travelers (80%), including the 10 symptomatic patients, reported using topical insect repellent daily.

Most cases of ATBF are reported in clusters of travelers exposed to ticks during game hunting or safaris, as described here (1,3–5). The estimated incidence of African tick-bite fever in safari travelers is 4%–5.3% (4) but higher incidence may be reported as emphasized in our study. In our study, epidemiologic and clinical data for the 10 symptomatic patients were obtained in accordance with current knowledge of ATBF (2).

Skin biopsy samples remain the best tool to isolate or detect *R. africae* (2,6). However, specific serologic tests, especially immunofluorescence assays, remain the most widely used microbiologic test worldwide (7). No commercially available test for ATBF exists but due to extensive cross-reactions between spotted fever group rickettsiosis, commercial kits based on the detection of *R. conorii* antibodies can be used for the diagnosis of ATBF. Most tourists reported using topical insect repellents without any efficacy. Applying repellents to exposed skin provides little protection against ticks because they can crawl underneath clothing and bite untreated portions of the body (8). Thus, treating clothing with synthetic pyrethroid insecticide is recommended to complement the topical repellant (8).

In conclusion, our study emphasizes the importance of ATBF as a common cause of flulike illness in travelers returning from South Africa, but with a higher rate than malaria, typhoid fever, or other tropical fevers. The most important clinical clues are the presence of clustered cases with multiple inoculation eschars. Healthcare professionals who are providing advice should inform persons traveling to endemic areas of Africa of the risk of contracting ATBF and the importance of protecting themselves against tick bites. Chemoprophylaxis with doxycycline is not recommended, however.

### Table. Epidemiologic, clinical, and serologic information for 10 patients with African tick-bite fever*

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex/age (y)</th>
<th>Tick bite</th>
<th>Delay before onset (d)</th>
<th>Fever</th>
<th>Headache</th>
<th>Myalgia</th>
<th>Eschar (site)</th>
<th>Skin rash</th>
<th>1st serum†</th>
<th>2nd serum†</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M/62</td>
<td>No</td>
<td>7</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Multiple (legs)</td>
<td>No</td>
<td>NA/64</td>
<td>NA/64</td>
<td>Probable</td>
</tr>
<tr>
<td>2</td>
<td>F/56</td>
<td>No</td>
<td>6</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Multiple (legs, arms)</td>
<td>No</td>
<td>64/32</td>
<td>64/128</td>
<td>Confirmed</td>
</tr>
<tr>
<td>3</td>
<td>M/58</td>
<td>No</td>
<td>6</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Single (trunk)</td>
<td>No</td>
<td>64/32</td>
<td>128/16</td>
<td>Confirmed</td>
</tr>
<tr>
<td>4</td>
<td>F/51</td>
<td>No</td>
<td>6</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Multiple (legs, trunk)</td>
<td>No</td>
<td>0/64</td>
<td>128/16</td>
<td>Confirmed</td>
</tr>
<tr>
<td>5</td>
<td>M/58</td>
<td>No</td>
<td>5</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Multiple (legs)</td>
<td>No</td>
<td>512/0</td>
<td>512/0</td>
<td>Confirmed</td>
</tr>
<tr>
<td>6</td>
<td>F/57</td>
<td>No</td>
<td>5</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes (unknown)</td>
<td>Yes</td>
<td>NA</td>
<td>32/16</td>
<td>Confirmed</td>
</tr>
<tr>
<td>7</td>
<td>M/65</td>
<td>No</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Multiple (hands)</td>
<td>No</td>
<td>128/64</td>
<td>512/128</td>
<td>Confirmed</td>
</tr>
<tr>
<td>8</td>
<td>F/59</td>
<td>No</td>
<td>10</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Multiple (legs, arms, trunk)</td>
<td>No</td>
<td>64/8</td>
<td>128/32</td>
<td>Confirmed</td>
</tr>
<tr>
<td>9</td>
<td>M/53</td>
<td>No</td>
<td>3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Multiple (legs)</td>
<td>Yes</td>
<td>0/0</td>
<td>1,024/512</td>
<td>Confirmed</td>
</tr>
<tr>
<td>10</td>
<td>M/51</td>
<td>No</td>
<td>8</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Multiple (legs)</td>
<td>No</td>
<td>32/32</td>
<td>64/64</td>
<td>Confirmed</td>
</tr>
</tbody>
</table>

*NA, not available; Ig, immunoglobulin; male-to-female ratio, 60%; mean age = 57.2 ± 4.5 years.
†Identical results obtained with both *Rickettsia africae* and *R. conorii* antigens.
however, this recommendation may be evaluated in future clinical trials.

Acknowledgments

We thank Paul Newton for English corrections.

Paul H. Consigny,*
Jean-Marc Rolain,† Daniel Mizzi,‡ and Didier Raoult§

*Institut Pasteur de Paris, Paris, France; †Université de la Méditerranée, Marseille, France; ‡Médecin de Santé au Travail, Plaisir, France; and Faculté de Médecine, Marseille, France

References


Address for correspondence: Didier Raoult, Unité des Rickettsies, Faculté de Médecine, 27, Boulevard Jean Moulin, 13385 Marseille CEDEX 5, France; fax: 33-04-91-38-77-72; email: Didier.Raoult@medecine.univ-mrs.fr

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.